Table 2.
Comparison of outcomes between DCIS and DCIS-MI.21
| Characteristic | DCIS | DCIS-MI | P |
|---|---|---|---|
| N = 321 | N = 72 | ||
| Age (years) | 0.45 | ||
| <50 | 113 | 22 | |
| ≥50 | 208 | 50 | |
| ER | 0.23 | ||
| Positive | 3 | 7 | |
| Negative | 7 | 5 | |
| Unknown | 311 | 60 | |
| PR | >0.99 | ||
| Positive | 3 | 4 | |
| Negative | 6 | 5 | |
| Unknown | 312 | 63 | |
| Hormonal therapy | 0.069 | ||
| Yes | 66 | 8 | |
| No | 250 | 62 | |
| Unknown | 5 | 2 | |
| Outcome | |||
| 10-year LRFS | 89% | 90.7% | 0.36 |
| 10-year DMFS | 98.5% | 97.9% | 0.77 |
| 10-year OS | 93.2% | 95.7% | 0.93 |
| Local relapse | 22 (6.8%) | 6 (8.3%) | 0.36 |
DCIS, ductal carcinoma in situ; DCIS-MI, DCIS with microinvasion; ER, estrogen receptor; PR, progesterone receptor; LRFS, local relapse-free survival; DMFS, distant metastasis-free survival; OS, overall survival.